Reframe Health, operating as Frame, sells a wrap-around clinical services layer that embeds inside in-person care providers, starting with fertility, turning OBGYNs and fertility clinics into more efficient triage, referral, and care-delivery engines. Frame's wedge is monetizing the provider side of fertility care through subscription and revenue-share inside existing clinic workflows, rather than competing for employer benefit dollars the way Progyny, Carrot, and Maven do. The company credentials under OBGYNs and bills for Frame services (roughly 25% revenue share on that side), while charging fertility clinics a subscription of about $20K to $70K per year, a model designed to flip toward higher-margin revenue-share and SaaS network products over time.
Validation is concrete: as of the 2025-09-05 note the team had 7 signed customers including Privia and other major provider networks, up from 2 to 3 a year earlier, and the 2025-09-19 note reports a Ferring pharma contract worth over $1M ARR ($100K implementation plus $75K per month). The 2025-10-22 update from Jessica reports the Ferring offering launched two months early and a first close of the priced Seed II with roughly $3M committed against a $2M to $3M target, plus a senior partnerships hire (Joe Cody, ex-Grain). The persistent drag, flagged since the 2024-06-27 diligence call and still visible in the 2025-09-19 activation data (only 40 of 2,000-plus signed doctors actively using Frame), is that revenue ramps slowly against signed potential. StoryHouse committed $600K from Fund II into the Seed II at a $23M post ($19.5M pre), on top of a prior Fund I $150K SAFE that converted at the Seed-3 share price.
The global fertility services market was estimated at roughly $42B in 2023 and is projected to reach about $70B by 2030 at a 7.5% CAGR (Web). The secular tailwind, delayed family formation, rising infertility rates, and expanding coverage, is real, but incumbents are largely employer-benefit navigators; Frame's bet is on the underserved provider-delivery side where clinician shortage and OBGYN training gaps (only about two weeks of fertility training in med school, per the 2024-06-27 note) create the wedge.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Reframe Health (Frame) | Provider-embedded wrap-around fertility services; subscription + revenue-share inside OBGYN and clinic workflows | Seed II, $3.1M @ $23M post | — |
| Progyny | Fertility benefits managed for employers, clinic network | Public, ~$2.7B EV | Sells to employers, not the provider delivery layer Frame owns |
| Kindbody | Owned clinics plus employer benefits | ~$1.8B valuation | Capital-heavy clinic build vs. Frame's asset-light provider overlay |
| Carrot Fertility | Employer fertility benefit and navigation | ~$500M valuation, $114M+ raised | Benefit navigator; does not monetize in-clinic care delivery |
| Maven Clinic | Virtual women's and family health clinic | Late-stage private | Virtual-first breadth vs. Frame's in-person provider integration |
Moat: Frame's defensibility is embedding into provider credentialing, billing, and clinical workflows (winning against 9 other solutions at Privia, per the 2024-06-27 note), which creates switching costs and a revenue position the employer-benefit incumbents do not touch.
The most probable exit is strategic acquisition by a fertility benefits platform (Progyny, Carrot, Maven), a large provider network already partnered with Frame (Privia, Unified, US Fertility), or a pharma sponsor such as Ferring seeking a distribution and engagement channel. Public and late-stage comps (Progyny ~$2.7B EV, Kindbody ~$1.8B) anchor the upside, but return math depends on Frame converting signed logos into revenue: at roughly $1.4M LTM against a $23M post, the entry multiple leaves limited room for slippage, so the case rests on activation and the higher-margin SaaS-network mix scaling.
Investor update from Jessica ahead of the first close: round oversubscribed relative to target, Ferring offering launching early, and a senior partnerships hire.
Update to Frame investors ahead of the first close, thanking participants. Commitments of roughly $3M with insiders plus a few additional new investors; original target was $2M to $3M.
On Monday 10/27 the company launches its initial offering with Ferring (pharma), two months early relative to the original launch date and an additional week early at Ferring's request; R&D and implementation teams are ahead of schedule, with a PR announcement to come later in the year.
New hire Joe Cody joins to lead ecosystems and partnerships alongside Jessica, growing the business with pharma, labs, and more; Joe previously ran a company in the space (Grain). The transition, announced ahead of the ASRM conference, references his prior company but was a hire of Joe specifically, not an M&A transaction. Jessica noted she would be at HLTH on Monday.
Follow-up diligence call with Jessica (Matthew Estes) covering the current revenue base, the activation gap, and the network rollout playbook.
Intro and intel source: SH portfolio founder. Deal status: In Conversation, follow track. First 30 minutes of a follow-up call with Frame (Matthew Estes and Jessica).
Current business model and revenue: 2,000-plus doctors signed across fertility networks, 300 individual providers available for referrals, but only 40 actively using Frame in August. August revenue was $46,000 from those 40 doctors (~$1,000 per doctor), a mix of per-physician monthly fees ($1,000 to $2,500) and referral-based revenue. Privia has 32 doctors referring at 12% referral-based revenue; fertility clinics have 8 to 9 active doctors. The Ferring contract is $100K implementation plus $75K per month ongoing, over $1M ARR.
Network rollout: fertility clinic expansion is phased, launching with 1 to 2 clinics then expanding regionally in 3 to 6 month phases, with full network rollout taking 12 to 18 months. US Fertility (25% of total market) launched March 2025 with 3 of 250 potential doctors, next phase expanding to 90 physicians in the DMV region. Implementation speed is improving (First Fertility 27 days, IVF 3 weeks).
Growth constraints: credentialing (3 to 6 months for new markets), provider awareness (doctors must remember to refer), and fertility-only scope. Planned improvements: decision-support flags for automatic diagnosis-based referrals, expansion beyond fertility, and earlier C-suite engagement. Target of 10 referrals per physician per month by 2027 (currently ~1.7). Each Privia doctor sees 80 to 120 potential Frame patients per week. Team handling rollout: Jessica part-time on BD, a full-time customer success leader for fertility clinics, and a part-time implementation consultant; the company needs replicable processes and KPIs to scale beyond current capacity.
Follow-up call (Jessica and Corey with Matthew and Miles) on financial projections, the raise, and fundraising-narrative feedback.
Frame and StoryHouse follow-up (Jessica Bell van der Wal, Matthew, Miles, Corey). Financial projections and funding strategy: default alive early 2027 with 6% EBITDA margin in the current model; with 42% gross margin could reach default alive mid-2026, but that would require very lean operations with the current 7.5 FTEs and decreased revenue acceleration. Fundraising range $1M to $3M on the existing SAFE (19 post): $1M for steady state servicing existing contracts, $2M to lean into opportunities with moderate acceleration, $3M to invest in core technology and pipeline. Early in the process, still TBD on interest; KLI Capital institutional investor discussed, and one original angel committed to super pro rata.
Customer base: now 7 signed customers (up from 2-3 previously mentioned), all signed and existing, some rolling out slowly and others at full scale, including Privia and other major healthcare providers. Revenue builds over time with large per-customer potential; product mix shifting toward higher-margin SaaS network products.
Fundraising feedback: Matt's key recommendation was to add building-block analysis to the pitch, showing unit economics for individual customers first, then compounding multiple customers with overhead, separating direct from indirect costs. The current deck is strong on concept but light on operational "how." Potential for customer co-investment partnerships, with pharma partners more open to upfront payments than providers, and a 3x ROI in 3 months claim potentially supporting upfront requests. Action items: finalize the financial model, create building-block slides, share an investor target list with StoryHouse for warm intros, and explore customer co-investment.